John Vandermosten photo

BIOTECH, HEALTHCARE, TECHNOLOGY

John Vandermosten

Senior Biotechnology Research Analyst,

Zacks Investment Research

  • Senior Biotechnology Research Analyst, Zacks Investment Research

About John

John Vandermosten is currently a senior biotechnology research analyst for Zacks Investment Research where he covers a portfolio of small-cap biotechnology names. His background includes 17 years of experience in a variety of investment management and research roles across all market cap ranges and throughout the capital structure. Formerly, Mr. Vandermosten was a research analyst for Singular Research covering the healthcare space and a consultant with Coker Group, a national healthcare services firm providing financial advisory, investment banking, healthcare IT, and other services to hospitals and other health care organizations.

John's Videos

John Vandermosten talks about the expansion of gene therapy and how it is used to combat auto-immune diseases.
John Vandermosten digs into the biotechnology sector. Learn the smoking cessation drugs likely to create value for biotech stocks.
At MoneyShow, John Vandermosten of Zacks Investment Research: one area big in cancer drugs has been checkpoint inhibitors, like Keytruda from Merck. They work well in about 20% of people.

John moderated a panel of Biotech CEOs earlier this week (October 1st) at the MicroCap Conference in NYC. The panel covered a variety of current topics of interest to investors including:


  • The role of pricing and transparency in health care
  • Why are we seeing new initiative like Civica Rx and the JP Morgan/Berkshire Hathaway/Amazon collaboration?
  • How do we address the fast growth of healthcare costs in the United States
  • How the FDA is changing
  • Immuno-oncology and the impact of new biologics in this space
  • Trends in Biotech-focused Venture Capital
  • Availability of capital in the biotech space and China's new role
  • Potential benefits from AI and technology on the healthcare space
  • Regulatory trends and how they impact capital decisions

  • John will share with MoneyShow what biotech CEOs are thinking and what investors are asking about these topics.